Navigation Links
Byetta Lawsuit News: Bernstein Liebhard LLP Awaits Decision on Establishment of Federal Multidistrict Litigation for Byetta Pancreatic Cancer Claims

New York, New York (PRWEB) July 20, 2013

As Byetta lawsuit claims continue to mount in courts throughout the country, Bernstein Liebhard LLP notes that the U.S. Judicial Panel on Multidistrict Litigation (JPML) is scheduled to hear Oral Arguments on July 25th regarding the possible establishment of a multidistrict litigation for all federal product liability claims involving Byetta and other type 2 diabetes drugs known as incretin mimetics. On April 29, Amylin and Eli Lilly, the manufacturers of Byetta, filed a response with the JPML voicing support for the proposed litigation. The companies also agreed that the U.S. District Court, Southern District of California would be the appropriate venue for the litigation. (In Re: Incretins Products Liability, Sales and Marketing Litigation, MDL 2452, JPML)

“We have received numerous inquiries from individuals seeking to file Byetta pancreatic cancer lawsuits, and continue to hear from others who allegedly developed pancreatitis or thyroid cancer due to this drug. We look forward to the Panel’s decision regarding the consolidation of these cases,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free Byetta lawsuit evaluations to patients who took this drug and were diagnosed with pancreatic cancer, thyroid cancer or pancreatitis.

Byetta Pancreatic Cancer Lawsuits
According to the Amylin and Eli Lilly filing, the companies have been named defendants in at least 42 Byetta pancreatic cancer lawsuits filed in courts throughout the country. All of the claims allege the companies concealed the association between Byetta and pancreatic cancer, and failed to provide adequate warnings regarding the drug’s risks.

Over the past several months, Byetta and other incretin mimetics have come under scrutiny, as concerns have mounted over their potentially harmful effects on the pancreas. On March 14, the U.S. Food & Drug Administration (FDA) announced it was investigating findings from an unpublished study that suggested Byetta and other incretin mimetics could be associated with pre-cancerous cellular changes in the pancreas called pancreatic duct metaplasia.* The month prior, a paper published in JAMA Internal Medicine reported that drugs like Byetta appeared to double the risk for pancreatitis, a known risk factor for pancreatic cancer.** A year earlier, research published in Gastroenterology found that Byetta increased the risk of pancreatic cancer by nearly 3-fold. The same study also reported 30 cases of thyroid cancer in patients taking the drug, and a six-fold increase risk for pancreatitis among Byetta users.***

According to Bernstein Liebhard LLP, multidistrict litigations like that proposed for Byetta lawsuits are established when a large number of complex cases share common allegations of facts. The aim of such a proceeding is to preserve the resources of the Court, parties and witnesses, and to avoid duplicative discovery and conflicting orders.

Byetta users who developed pancreatic cancer, pancreatitis or thyroid cancer may be entitled to compensation for medical bills, lost wages, and pain and suffering. Additional information about filing a Byetta lawsuit is available at Bernstein Liebhard LLP’s website. To learn more, please call 800-511-5092.

*, FDA, March 14, 2013
**, JAMA Internal Medicine, February 25, 2013
***, Gastroenterology, February 21, 2011

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. d'Oliveira & Associates Releases New Byetta Infographic on Potential Kidney and Pancreas Health Risks Associated with the Drug
2. Byetta Pancreatic Cancer Allegation Lawsuits Offered through Resource4thePeople
3. DrugRisk Announces Launch of Byetta Cancer Resource Center
4. Pancreatic Cancer Correlation to Type 2 Diabetes Drugs Januvia and Byetta, New Studies Find Possible Connection
5. DrugRisk Update: New Study Warns of Cancer in Byetta Side Effects
6. Byetta Lawsuit News: Woman Alleges Her Thyroid Cancer Is Linked to Byetta Use, Rottenstein Law Group LLP Reports
7. DrugRisk Update: Byetta Maker Agrees With Transferring Lawsuits to Federal Court
8. Byetta Lawyers at Gilman Law, a Leading Pharmacy Law and Defective Drug Plaintiffs’ Law Firm, Troubled by Growing Byetta Pancreatic Cancer Reports
9. Diabetes Drug Byetta Caused Arkansas Man’s Pancreatic Cancer and Resulting Injuries, Alleges Lawsuit Filed by Parker Waichman LLP and Co-Counsel
10. Rottenstein Law Group LLP Comments on Drugmakers’ Cooperation With Safety Review of Byetta, Januvia, Victoza
11. Byetta Pancreatic Cancer Lawsuit News: Bernstein Liebhard LLP Comments on BMJ Investigation Finding Incretin Mimetic Risks Were Downplayed
Post Your Comments:
(Date:11/30/2015)... ... 30, 2015 , ... Until now, the St. Louis Fetal Care Institute ... of Myelomeningocele Study) trial. One of these exclusion criteria was a BMI above 34.9. ... to 24.9 is considered normal, 25 - 29.9 is overweight and above 30 is ...
(Date:11/30/2015)... ... November 30, 2015 , ... Thermi™, a world ... announce that its ThermiRFR temperature controlled radiofrequency platform has received CE marking and ... platform which uses temperature as a clinical endpoint. The technology has been ...
(Date:11/30/2015)... ... November 30, 2015 , ... The world of hair transplants and restoration is ... These techniques and procedures have been in use for many years and are among ... Parsa Mohebi, M.D. has utilized many of these methods over the years, he also ...
(Date:11/30/2015)... ... November 30, 2015 , ... The presidential race normally ... styling. So why is it a national news story when Donald Trump makes disparaging ... M.D., because appearances count more than anyone wants to admit when it comes to ...
(Date:11/30/2015)... , ... November 30, 2015 , ... According to Los ... people to overeat are not necessarily caused by real hunger, but instead by ... needs food. He notes that, while many patients are aware that weight loss surgery ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... 2015   Royal Philips  (NYSE: PHG ... Radiology Solutions, a fully integrated, consultative approach to ... data-driven practice management approaches that combine imaging systems, ... improve care delivery and reduce costs. Making its ... North America Annual Meeting (RSNA) in ...
(Date:11/30/2015)... -- global cell culture market is expected to ... by 2022 at a CAGR of 7.1% therein. --> ... 2013 value of US$6.1 bn to US$11.3 bn by 2022 at ... has announced the release of a new market research study, detailing ... Culture Market - Global Industry Analysis, Size, Share, Growth, Trends and ...
(Date:11/30/2015)... , Nov. 30, 2015   Royal Philips ... Implant, the industry,s first MRI guided user interface and ... of patients with MR Conditional implants, such as knee ... 2015 Radiological Society of North America Annual Meeting ... and supports diagnostic confidence of this growing patient population. ...
Breaking Medicine Technology: